Patents Examined by T. D. Wessendorf
  • Patent number: 6821737
    Abstract: Method and kits are provided for screening for transcription factor modulators efficiently. In one aspect, the method can be employed to profile multiple, different transcription factors activated in a sample in the presence of each of the transcription factor modulators. Comparison of the activated transcription factor profiles in the presence and absence of the modulator identifies the transcription factor modulator that modulates the activation of specific transcription factors.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: November 23, 2004
    Assignee: Panomics, Inc.
    Inventor: Xianqiang Li
  • Patent number: 6818411
    Abstract: This invention provides methods of retentate chromatography for resolving analytes in a sample. The methods involve adsorbing the analytes to a substrate under a plurality of different selectivity conditions, and detecting the analytes retained on the substrate by desorption spectrometry. The methods are useful in biology and medicine, including clinical diagnostics and drug discovery.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: November 16, 2004
    Assignee: Ciphergen Biosystems, Inc.
    Inventors: T. William Hutchens, Tai-Tung Yip
  • Patent number: 6800449
    Abstract: A method is disclosed which provides a high throughput method for assigning plausible functions to unknown sequence entries in a particular database. The method was used herein to identify lectin proteins which can be found in specific tissues of the rice plant.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: October 5, 2004
    Assignee: Syngenta Participations AG
    Inventors: Paul A. Haynes, Nancy L. Andon
  • Patent number: 6790624
    Abstract: Fusion proteins containing coiled-coil heterodimerization domains substituted for modular protein binding domains useful for validating functionally relevant protein-protein interactions, directing enzymes to specific substrates, and screening fusion libraries for functionally important interaction partners.
    Type: Grant
    Filed: March 24, 2001
    Date of Patent: September 14, 2004
    Assignee: The University of Connecticut
    Inventor: Bruce J. Mayer
  • Patent number: 6780599
    Abstract: The present invention provides assays using fusion proteins with GFP fragments and test polypeptides for investigating protein-protein interactions.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: August 24, 2004
    Assignee: Yale University
    Inventors: Andrew D. Hamilton, Indraneel Ghosh, Lynne Regan
  • Patent number: 6762031
    Abstract: Methods for creating viral display libraries for purposes of isolating variants with modified target cell specificity and related methods; also retroviral display libraries.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: July 13, 2004
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Monica Judith Roth, Keith Bupp
  • Patent number: 6759510
    Abstract: The present invention provides peptides libraries which are useful for rapid identification of biologically active compounds. The invention further provides peptides which include cell-growth affecting peptides and peptides which enhance or inhibit production of cellular proteins. Many of the peptides of the invention may be produced in large quantity by recombinant techniques and formulated in culture medium to produce the desired effect on cultured cells and tissues. Certain of the libraries of the invention and the peptides identified in them are particularly useful in concatemer-based recombinant expression methods.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: July 6, 2004
    Assignee: Becton, Dickinson and Company
    Inventors: Perry D. Haaland, Douglas B. Sherman, Robert L. Campbell, Walter William Stewart, Sheila A. Lloyd, Bruce Wayne Erickson
  • Patent number: 6747125
    Abstract: Peptides which include unnatural amino acids and which either promote or inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such peptides that are GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads and may be used to treat steroid-dependent tumors. The agonists can be used for control of reproduction processes, to treat precocious puberty, endometriosis, and the like. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-, 5-, 6- and/or 8-positions.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: June 8, 2004
    Assignee: The Salk Institute for Biological Studies
    Inventors: Carl A. Hoeger, Jean E. F. Rivier, Paula Guess Theobald, John S. Porter
  • Patent number: 6743630
    Abstract: A method of preparing a protein array based on biochemical protein-protein interaction is provided. An array of a first protein which includes a PDZ domain is deposited on a substrate. A second protein, which includes an amino acid sequence (S/T)—X—(V/I/L)—COOH (each hyphen represents a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, each slash within such parentheses separates the alternative amino acids, and the X represents any amino acid which is selected from the group comprising the twenty naturally occurring amino acids), is applied to the first protein array. The amino acid sequence (S/T)—X—(V/I/L)—COOH of the second protein is bound to the PDZ domain of the first protein.
    Type: Grant
    Filed: March 6, 2002
    Date of Patent: June 1, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Taka-Aki Sato
  • Patent number: 6737241
    Abstract: Methods and compositions for screening for intracellular transdominant effector peptides and RNA molecules selected inside living cells from randomized pools are provided.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Garry P. Nolan
  • Patent number: 6737240
    Abstract: The invention relates generally to methods of screening for drugs which bind to and/or regulate cellular proteins involved in drug resistance, particularly resistance of tumor cells to chemotherapeutic agents.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ziang Xu, Donald Payan
  • Patent number: 6720171
    Abstract: A process for preparing arrays of two or more heterogeneous catalysts, heterogeneous catalyst precursors, or combinations thereof in a body having preferably parallel through-channels. In this process, a solution, emulsion or dispersion of elements present in the catalyst, catalyst precursor, or combination thereof, is first prepared, and is used to simultaneously or successively coat the channels of the body to produce freshly impregnated moist channels. These channels are then treated and reacted with one or more reactive gases, and the coated body is optionally heated in the presence or absence of inert or reactive gases.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 13, 2004
    Assignee: BASF Aktiengesellschaft
    Inventors: Stephan Andreas Schunk, Dirk Demuth, Hartmut Hibst
  • Patent number: 6713604
    Abstract: The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of &agr;4&bgr;1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses &agr;4&bgr;1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
    Type: Grant
    Filed: May 8, 1996
    Date of Patent: March 30, 2004
    Assignee: Texas Biotechnology Corporation
    Inventors: Timothy P. Kogan, Kaijun Ren, Peter Vanderslice, Pamela J. Beck
  • Patent number: 6703482
    Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from three phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins of SH3 domains and glutathione S-transferase (GST). Preferred peptides are disclosed having a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: March 9, 2004
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Brian K. Kay, Andrew B. Sparks, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der
  • Patent number: 6696256
    Abstract: Methods, arrays and kits are provided for rapidly and efficiently identifying and quantifying multiple different activated transcription factors in a biological sample at the same time. In one embodiment, the method includes the step of mixing a library of transcription factor probes with a sample containing activated transcription factors. The transcription factor probes that have bound to the activated transcription factors may be isolated from the complexes formed between the probes and the activated transcription factors. The bound probes can be identified, for example, by using an array of hybridization probes.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: February 24, 2004
    Assignee: Pandmics, Inc.
    Inventor: Xianqiang Li
  • Patent number: 6696620
    Abstract: Arrays of immunoglobulin binding proteins in plants or plant cells are provided. Such arrays comprise plants or plant cells transformed with polynucleotides encoding multiple different immunoglobulin binding proteins, or polypeptide components thereof. Methods are further provided for genetic segregation of the transformation events such that each transformant in an array is capable of producing progeny capable of expressing one or more immunoglobulin binding proteins, including multi-subunit proteins.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: February 24, 2004
    Assignee: Epicyte Pharmaceutical, Inc.
    Inventors: Andrew C. Hiatt, Mich B. Hein
  • Patent number: 6682886
    Abstract: Described herein are methods for identifying and preparing bivalent binding molecules to 7 transmembrane G protein-coupled receptors. The methods disclosed herein are based on the SELEX method for generating high affinity nucleic acid ligands. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The methods of this invention combine two or more binding domains to two or more different epitopes of the same 7 transmembrane G protein-coupled receptor. These bivalent binding molecules are useful as therapeutic and diagnostic agents.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: January 27, 2004
    Assignee: Gilead Sciences, Inc.
    Inventor: Larry Gold
  • Patent number: 6676946
    Abstract: A carbohydrate peptide conjugate containing: (i) a carrier containing a dendrimeric poly-lysine enabling multiple epitopes to be covalently attached thereto, (ii) at least one peptide containing one T epitope or several identical or different T-epitopes, (iii) at least one carbohydrate moiety which is tumor antigen, or a derivative thereof, containing a B epitope, provided it is not a sialoside, or several identical or different epitopes, wherein said conjugate containing at least 3-lysines and up to 15 lysine covalently linked to one another, and wherein: (a) to the NH2 and of at least two lysine residues is bound at least one carbohydrate residue being not a sialoside, optionally substituted and containing an epitope and wherein the peptide containing one T epitope is covalently bound to the end of said carbohydrate which induces immune responses.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: January 13, 2004
    Assignee: Institut Pasteur
    Inventors: Sylvie Bay, Daniele Cantacuzene, Claude Leclerc, Richard Lo-Man, Sophie Vicher-Guerre
  • Patent number: 6670142
    Abstract: The invention includes a cell-growth-on-bead assay for screening a one-bead-one-compound combinatorial bead library to identify synthetic ligands for cell attachment and growth or proliferation of epithelial cells. Cells are incubated with a compound bead library for 24 to 72-hours, allowing them to attach and grow on the beads. Those beads with cells growing are removed, and the ligand on the bead is identified. Also provided are ligands specific for epithelial cancer cells. The invention also includes a method of capturing epithelial cells from body fluids. In this method, beads are prepared with a known ligand specific for a particular type of cell and incubated for 24 to 72 hours with a sample of the body fluid being tested. Those cells attached to the beads are removed and identified.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: December 30, 2003
    Assignee: The Regents of the University of California
    Inventors: Derick H. Lau, Kit S. Lam
  • Patent number: 6664367
    Abstract: Stable analogs of cyclic peptides containing disulfide linkages are disclosed. The disulfide linkage is modified by one of four methods: (a) sulfide contraction, (b) isosteric substitution, (c) thioketal expansion, or (d) alkylation expansion. In sulfide contraction the disulfide bond (—S—S—) is replaced with a monosulfide bond (—S—) in which a bifunctional effector molecule, such as a ligand or chemotoxic agent, is bound to the new peptide linkage. In isosteric substitution, one sulfur atom is replaced with a carbon atom and at least one of the carbon atoms at the modified site is a bifunctional effector molecule. In thioketal expansion, an alkylidene unit (—CR1C2—) is inserted between the two sulfur atoms. In alkylation expansion, an alkyl moiety of from C2 to C3, is inserted between the two sulfur atoms.
    Type: Grant
    Filed: July 21, 1994
    Date of Patent: December 16, 2003
    Assignee: Biosynthema, Inc.
    Inventors: Raghavan Rajagopalan, Ananthachari Srinivasan, Leon R. Lyle